Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: Quality of life in high-risk prostate cancer patients

Seok Ho Kang, Jin Wook Kim, Jae Hyun Bae, Hong Seok Park, Du Geon Moon, Duck Ki Yoon, Jun Cheon, Je-Jong Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: To present preliminary results on health-related quality of life (QoL), prostate-associated symptoms and therapeutic effects of targeted-cryosurgical ablation of the prostate (TCSAP) with androgen deprivation therapy (ADT) in high-risk prostate cancer (PCa) patients. Methods: Thirty-four men with high-risk PCa features underwent TCSAP, and ADT was added to improve the treatment outcomes. High-risk parameters were defined as either prostate-specific antigen (PSA) ≥ 10ng/mL, or Gleason score ≥ 8, or both. The Genito-Urinary Group of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) with prostate-cancer-specific module (QLQ-PR25) was used for evaluating morbidities and PSA levels were recorded every 3 months. PSA failure was defined as the inability to reach a nadir of 0.4 ng/mL or less. Results: Although it was not statistically significant, the global health status scores increased after TCSAP with ADT. The scores for five functional scales also became higher after treatment. The most prominent symptom after treatment was sexual dysfunction, followed by treatment-related and irritative voiding symptoms. Conclusion: TCSAP with ADT appears to be minimally invasive with high QoL except for sexual dysfunction. Long-term follow-up of PSA data and survival is necessary before any conclusions can be made on the efficacy of this promising new therapeutic modality in the treatment of PCa.

Original languageEnglish
Pages (from-to)629-636
Number of pages8
JournalAsian Journal of Andrology
Volume8
Issue number5
DOIs
Publication statusPublished - 2006 Sep 1

Fingerprint

Androgens
Prostate
Prostatic Neoplasms
Quality of Life
Prostate-Specific Antigen
Therapeutics
Neoplasm Grading
Therapeutic Uses
Health Status
Organizations
Morbidity
Survival
Research

Keywords

  • Cryosurgery
  • EORTCQLQ-C30
  • Hormone antagonist
  • Prostate cancer
  • Prostatic neoplasm
  • Quality of life
  • Targeted-cryosurgical ablation of the prostate

ASJC Scopus subject areas

  • Urology

Cite this

@article{91a92be2993a4f629e26deab809e08f1,
title = "Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: Quality of life in high-risk prostate cancer patients",
abstract = "Aim: To present preliminary results on health-related quality of life (QoL), prostate-associated symptoms and therapeutic effects of targeted-cryosurgical ablation of the prostate (TCSAP) with androgen deprivation therapy (ADT) in high-risk prostate cancer (PCa) patients. Methods: Thirty-four men with high-risk PCa features underwent TCSAP, and ADT was added to improve the treatment outcomes. High-risk parameters were defined as either prostate-specific antigen (PSA) ≥ 10ng/mL, or Gleason score ≥ 8, or both. The Genito-Urinary Group of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) with prostate-cancer-specific module (QLQ-PR25) was used for evaluating morbidities and PSA levels were recorded every 3 months. PSA failure was defined as the inability to reach a nadir of 0.4 ng/mL or less. Results: Although it was not statistically significant, the global health status scores increased after TCSAP with ADT. The scores for five functional scales also became higher after treatment. The most prominent symptom after treatment was sexual dysfunction, followed by treatment-related and irritative voiding symptoms. Conclusion: TCSAP with ADT appears to be minimally invasive with high QoL except for sexual dysfunction. Long-term follow-up of PSA data and survival is necessary before any conclusions can be made on the efficacy of this promising new therapeutic modality in the treatment of PCa.",
keywords = "Cryosurgery, EORTCQLQ-C30, Hormone antagonist, Prostate cancer, Prostatic neoplasm, Quality of life, Targeted-cryosurgical ablation of the prostate",
author = "Kang, {Seok Ho} and Kim, {Jin Wook} and Bae, {Jae Hyun} and Park, {Hong Seok} and Moon, {Du Geon} and Yoon, {Duck Ki} and Jun Cheon and Je-Jong Kim",
year = "2006",
month = "9",
day = "1",
doi = "10.1111/j.1745-7262.2006.00176.x",
language = "English",
volume = "8",
pages = "629--636",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy

T2 - Quality of life in high-risk prostate cancer patients

AU - Kang, Seok Ho

AU - Kim, Jin Wook

AU - Bae, Jae Hyun

AU - Park, Hong Seok

AU - Moon, Du Geon

AU - Yoon, Duck Ki

AU - Cheon, Jun

AU - Kim, Je-Jong

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Aim: To present preliminary results on health-related quality of life (QoL), prostate-associated symptoms and therapeutic effects of targeted-cryosurgical ablation of the prostate (TCSAP) with androgen deprivation therapy (ADT) in high-risk prostate cancer (PCa) patients. Methods: Thirty-four men with high-risk PCa features underwent TCSAP, and ADT was added to improve the treatment outcomes. High-risk parameters were defined as either prostate-specific antigen (PSA) ≥ 10ng/mL, or Gleason score ≥ 8, or both. The Genito-Urinary Group of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) with prostate-cancer-specific module (QLQ-PR25) was used for evaluating morbidities and PSA levels were recorded every 3 months. PSA failure was defined as the inability to reach a nadir of 0.4 ng/mL or less. Results: Although it was not statistically significant, the global health status scores increased after TCSAP with ADT. The scores for five functional scales also became higher after treatment. The most prominent symptom after treatment was sexual dysfunction, followed by treatment-related and irritative voiding symptoms. Conclusion: TCSAP with ADT appears to be minimally invasive with high QoL except for sexual dysfunction. Long-term follow-up of PSA data and survival is necessary before any conclusions can be made on the efficacy of this promising new therapeutic modality in the treatment of PCa.

AB - Aim: To present preliminary results on health-related quality of life (QoL), prostate-associated symptoms and therapeutic effects of targeted-cryosurgical ablation of the prostate (TCSAP) with androgen deprivation therapy (ADT) in high-risk prostate cancer (PCa) patients. Methods: Thirty-four men with high-risk PCa features underwent TCSAP, and ADT was added to improve the treatment outcomes. High-risk parameters were defined as either prostate-specific antigen (PSA) ≥ 10ng/mL, or Gleason score ≥ 8, or both. The Genito-Urinary Group of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) with prostate-cancer-specific module (QLQ-PR25) was used for evaluating morbidities and PSA levels were recorded every 3 months. PSA failure was defined as the inability to reach a nadir of 0.4 ng/mL or less. Results: Although it was not statistically significant, the global health status scores increased after TCSAP with ADT. The scores for five functional scales also became higher after treatment. The most prominent symptom after treatment was sexual dysfunction, followed by treatment-related and irritative voiding symptoms. Conclusion: TCSAP with ADT appears to be minimally invasive with high QoL except for sexual dysfunction. Long-term follow-up of PSA data and survival is necessary before any conclusions can be made on the efficacy of this promising new therapeutic modality in the treatment of PCa.

KW - Cryosurgery

KW - EORTCQLQ-C30

KW - Hormone antagonist

KW - Prostate cancer

KW - Prostatic neoplasm

KW - Quality of life

KW - Targeted-cryosurgical ablation of the prostate

UR - http://www.scopus.com/inward/record.url?scp=33747619193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747619193&partnerID=8YFLogxK

U2 - 10.1111/j.1745-7262.2006.00176.x

DO - 10.1111/j.1745-7262.2006.00176.x

M3 - Article

C2 - 16847531

AN - SCOPUS:33747619193

VL - 8

SP - 629

EP - 636

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 5

ER -